Company: Kodiak Sciences
Job title: Chief Medical Officer and Chief Development Officer
Dr. Ehrlich serves as Chief Medical Officer and Chief Development Officer at Kodiak. Dr Ehrlich is internationally recognized for his leadership and expertise in ophthalmic drug development. Prior to joining Kodiak, Dr. Ehrlich served in an executive capacity as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group. In roles of increasing responsibility at Genentech/Roche from 2008-2018, Dr. Ehrlich’s efforts as lead clinician for Lucentis in diabetic eye disease resulted in a unanimous FDA Advisory Committee vote and the first-ever FDA approval of an intraocular drug for diabetic macular edema. He then championed filing of a collaborative group study to further expand the Lucentis labeling into all forms of diabetic retinopathy, resulting in another first-ever FDA approval that provided a new option for patients: to be treated with anti-VEGF to achieve regression of their diabetic retinopathy disease. Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System. In his work, Dr. Ehrlich has participated in or overseen numerous sBLAs and both FDA and European health authority interactions. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1,800 patients, over 275 sites, and more than 20 countries. He also oversaw his team’s effort to secure FDA approvals for Lucentis in its Prefilled Syringe and for choroidal neovascularization due to pathologic myopia and guided the successful transition to global Phase III development of Faricimab, a novel bispecific antibody for retinal vascular disease. Dr. Ehrlich completed his Ophthalmology residency at Stanford University School of Medicine, earned his M.D. and Ph.D. degrees from Stanford through the NIH-funded Medical Scientist Training Program, and received his A.B. in Molecular Biology summa cum laude from Princeton University.
Chair Led Q&A: Latest Case Studies Tackling the VEGF Pathway 12:55 pm
day: Day Two
KSI-301: An antibody-biopolymer conjugate for extended durability in retinal diseases 12:30 pm
Biophysical and biochemical principles of Kodiak Sciences’ antibody-biopolymer conjugate (ABC) platform Leveraging precise engineering of ABCs to achieve improved clinical outcomes in wet AMD, DME, and retinal vein occlusion An overview of preclinical and clinical studies to-date involving KSI-301, the first ABC for retinal diseasesRead more
day: Day Two